

# Combined Point-of-Care Nucleic Acid and Antibody Test Emergence of D614G Spike Variant

Cell Reports Medicine

1, 100099

DOI: [10.1016/j.xcrm.2020.100099](https://doi.org/10.1016/j.xcrm.2020.100099)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	1.8	38
2	A high-throughput multiplexed microfluidic device for COVID-19 serology assays. <i>Lab on A Chip</i> , 2021, 21, 93-104.	3.1	53
3	Diagnostic value of using a combination of nucleic acid and specific antibody tests for SARS-CoV-2 in coronavirus disease 2019. <i>Epidemiology and Infection</i> , 2021, 149, e62.	1.0	1
4	The role of pseudotype neutralization assays in understanding SARS CoV-2. <i>Oxford Open Immunology</i> , 2021, 2, iqab005.	1.2	20
5	Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports. <i>International Health</i> , 2022, 14, 18-52.	0.8	11
7	SARS-CoV-2 evolution during treatment of chronic infection. <i>Nature</i> , 2021, 592, 277-282.	13.7	802
8	Evaluation of the MP Rapid 2019-NCOV IgM/IgG combo POCT test vs. an established platform-based method. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 000456322199555.	0.8	2
9	Admission COVID-19 clinical risk assessment for guiding patient placement and diagnostic testing strategy. <i>Clinical Medicine</i> , 2021, 21, e140-e143.	0.8	1
10	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. <i>Wellcome Open Research</i> , 2021, 6, 56.	0.9	7
11	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgGâ„¢ lateral flow assay. <i>PLoS ONE</i> , 2021, 16, e0247797.	1.1	20
13	Extraction-free RT-LAMP to detect SARS-CoV-2 is less sensitive but highly specific compared to standard RT-PCR in 101 samples. <i>Journal of Clinical Virology</i> , 2021, 136, 104764.	1.6	22
14	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	13.7	648
15	Samba II PCR testing for COVID-19 in pregnant women: a retrospective cohort study and literature review. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 212.	0.9	3
16	Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. <i>The Cochrane Library</i> , 2022, 2022, CD013705.	1.5	482
17	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , 2021, 16, e0249791.	1.1	6
18	Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST). <i>Vaccines</i> , 2021, 9, 376.	2.1	1
19	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. <i>Heliyon</i> , 2021, 7, e06836.	1.4	11
21	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549

#	ARTICLE	IF	CITATIONS
22	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	6.6	230
24	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	2.9	375
25	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021, 11, 128.	2.1	9
26	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. <i>Translational Medicine Communications</i> , 2021, 6, 13.	0.5	1
27	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <i>Critical Care</i> , 2021, 25, 244.	2.5	186
28	SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. <i>Journal of Infectious Diseases</i> , 2021, 224, 989-994.	1.9	136
30	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
31	Multiplex Biosensing for Simultaneous Detection of Mutations in SARS-CoV-2. <i>ACS Omega</i> , 2021, 6, 25846-25859.	1.6	21
32	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. <i>Wellcome Open Research</i> , 2021, 6, 56.	0.9	28
33	Test, trace, isolate: evidence for declining SARS-CoV-2 PCR sensitivity in a clinical cohort. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115392.	0.8	7
38	The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature. <i>Viruses</i> , 2021, 13, 40.	1.5	50
39	More Aggressive Cancer Behaviour in Thyroid Cancer Patients in the Post-COVID-19 Pandemic Era: A Retrospective Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7197-7206.	0.8	14
41	SARS-CoV-2 prevalence at eight urban health clinics in Nicaragua: possible implications for the COVID-19 pandemic. <i>IJID Regions</i> , 2022, 2, 110-117.	0.5	0
43	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
45	A Sanger sequencing-based method for a rapid and economic generation of SARS-CoV-2 epidemiological data: A proof of concept study to assess the prevalence of the A23403G SNP (D614G) mutation in Quito, Ecuador. <i>F1000Research</i> , 0, 11, 383.	0.8	0
46	Emerging clinically tested detection methods for COVID-19. <i>FEBS Journal</i> , 2023, 290, 3089-3104.	2.2	1
50	Indicators of recent COVID-19 infection status: findings from a large occupational cohort of staff and postgraduate research students from a UK university. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
51	SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. <i>Cell Reports</i> , 2022, 40, 111220.	2.9	24

#	ARTICLE	IF	CITATIONS
52	Cyclin D3 restricts SARS-CoV-2 envelope incorporation into virions and interferes with viral spread. EMBO Journal, 2022, 41, .	3.5	9
54	Promising on-site and rapid SARS-CoV-2 detection via antigens. Frontiers in Public Health, 0, 10, .	1.3	0
55	A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood. Advanced Science, 2022, 9, .	5.6	20
56	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nature Communications, 2022, 13, .	5.8	14
57	A prevalence study of COVID-19 among healthcare workers in a pandemic hospital in the Samsun province of Turkey. PLoS ONE, 2022, 17, e0279067.	1.1	0
58	COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. MedComm, 2023, 4, .	3.1	19